Core Concepts
SGLT2 inhibitors reduce AF recurrences in T2D patients post-ablation.
Abstract
The study analyzed 13,340 adults with T2D and AF who underwent AF ablation, comparing those on SGLT2 inhibitors to those who were not. Key findings include:
Patients on SGLT2 inhibitors had significantly lower rates of recurrent AF.
Ablation failure was less common in the SGLT2 inhibitor group.
All-cause mortality, heart failure exacerbations, and hospitalizations were lower in the SGLT2 inhibitor group.
Prospective studies are needed to validate these findings.
The study had limitations related to observational data and potential confounding factors.
Stats
Primary study outcome showed a significant adjusted odds ratio of 0.68 for ablation failure with SGLT2 inhibitor treatment.
Probability of event-free survival at 12 months was 66% with SGLT2 inhibitor treatment and 61% without.
All-cause mortality was significantly lower with an adjusted odds ratio of 0.62 for patients on SGLT2 inhibitors.
Heart failure exacerbations and all-cause hospitalizations were roughly 20% lower with SGLT2 inhibitor treatment.
Quotes
"The findings generate an important hypothesis, and further prospective studies are needed to validate these findings in patients with type 2 diabetes and AF who have undergone AF ablation." - Authors